Drug intelligence / Profile preview

ExaNK

Development stage: Preclinical
Lead developer: Brooklyn ImmunoTherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

ExaNK is an allogeneic, off-the-shelf, induced pluripotent stem cell (iPSC)-derived Natural Killer (NK) cell therapy developed by Exacis Biotherapeutics. It is produced using Exacis's proprietary non-viral, mRNA-based gene editing platform. ExaNK is designed to harness the immune system for superior performance against hematologic and solid tumors.

Beyond the preview

Go deeper on ExaNK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExaNK.

Explore the full profile